Effect of oral anticoagulants on the outcome of faecal immunochemical test.
BACKGROUND
We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening.


METHODS
Individuals aged 50-69 years were invited to receive one FIT sample (cutoff 75 ng ml(-1)) between November 2008 and June 2011.


RESULTS
Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend=0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3-1.8; P=0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4-10.8; P=0.4).


CONCLUSIONS
Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.
Department of Gastroenterology, Hospital Universitario Donostia, Instituto Biodonostia, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain.
L
L
Bujanda
Hospital Universitario Donostia, Instituto Biodonostia, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), San Sebastián, Spain.
C
C
Sarasqueta
Department of Gastroenterology, University of Zaragoza, IIS Aragón, CIBERehd, Zaragoza, Spain.
Á
Á
Lanas
Department of Gastroenterology, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain.
E
E
Quintero
Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
J
J
Cubiella
Servicio de Aparato Digestivo, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
V
V
Hernandez
Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain.
J D
JD
Morillas
Department of Gastroenterology, Hospital Fundación Alcorcón, Madrid, Spain.
T
T
Perez-Fernández
Programa de Cribado de Cáncer Colorrectal, Dirección General de Salud Pública, Conselleria de Sanitat, Valencia, Spain.
D
D
Salas
Department of Gastroenterology, Hospital del Mar, IMIM, Barcelona, Catalonia, Spain.
M
M
Andreu
Unidad de Gestión Clínica de Digestivo, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
F
F
Carballo
Department of Gastroenterology, Hospital del Mar, IMIM, Barcelona, Catalonia, Spain.
X
X
Bessa
Centro Coordinador del Programa de Cribado Cáncer Colorrectal, Organización Central de Osakidetza-Servicio Vasco de Salud, Bilbao, Spain.
I
I
Portillo
Department of Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain.
R
R
Jover
Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.
F
F
Balaguer
Department of Gastroenterology, Hospital Universitario Donostia, Instituto Biodonostia, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain.
A
A
Cosme
Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.
A
A
Castells
D000925:Anticoagulants / Q000008:administration & dosage*; D003113:Colonoscopy / Q000379:methods; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000517:prevention & control; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D007120:Immunochemistry / Q000379:methods; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D009780:Occult Blood
D000925:Anticoagulants